The stock of BioRestorative Therapies Inc (NASDAQ: BRTX) has increased by 6.38 when compared to last closing price of 1.88.Despite this, the company has seen a gain of 12.35% in its stock price over the last five trading days. globenewswire.com reported 2025-06-09 that – New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and pharma – – BioRestorative to release new clinical data to the public prior to market open on June 13th – MELVILLE, N.Y., June 09, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD) will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, held June 11–14, 2025, in Hong Kong.
Is It Worth Investing in BioRestorative Therapies Inc (NASDAQ: BRTX) Right Now?
The stock has a 36-month beta value of 76.40. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BRTX is 5.43M, and at present, short sellers hold a 2.61% of that float. On June 13, 2025, the average trading volume of BRTX was 73.18K shares.
BRTX’s Market Performance
The stock of BioRestorative Therapies Inc (BRTX) has seen a 12.35% increase in the past week, with a 16.67% rise in the past month, and a 23.46% gain in the past quarter. The volatility ratio for the week is 2.97%, and the volatility levels for the past 30 days are at 2.90% for BRTX. The simple moving average for the past 20 days is 15.20% for BRTX’s stock, with a 15.97% simple moving average for the past 200 days.
BRTX Trading at 14.08% from the 50-Day Moving Average
After a stumble in the market that brought BRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.57% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BRTX starting from Broadrick Dale, who sale 1,112 shares at the price of $1.58 back on Oct 28 ’24. After this action, Broadrick Dale now owns 445,933 shares of BioRestorative Therapies Inc, valued at $1,757 using the latest closing price.
Stock Fundamentals for BRTX
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- 0.92 for the gross margin
The net margin for BioRestorative Therapies Inc stands at -30.94. The total capital return value is set at -1.99. Equity return is now at value -117.16, with -85.55 for asset returns.
Currently, EBITDA for the company is -11.37 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 35.24. The receivables turnover for the company is 15.64for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.
Conclusion
To sum up, BioRestorative Therapies Inc (BRTX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
